Last reviewed · How we verify

NCT06340516

NT-proBNP to Assess Trastuzumab-induced Cardiotoxicity

Recruiting now NA Last updated 1 April 2024
What this trial tests

NA trial testing Plasma NT-proBNP in Cardiotoxicity in 700 participants. Currently enrolling.

Timeline
14 March 2024
Primary endpoint
14 March 2029
14 March 2029

Quick facts

Lead sponsorVastra Gotaland Region
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment700
Start date14 March 2024
Primary completion14 March 2029
Estimated completion14 March 2029
Sites1 location across Sweden

Drugs / interventions tested

Conditions studied

Sponsor

Vastra Gotaland Region — full company profile →

Who can join

18 and older, any sex, with Cardiotoxicity or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Trastuzumab-induced cardiotoxicity (TIC) will be monitored in patients with HER2+ breast cancer undergoing trastuzumab treatment before and after breast cancer surgery. At baseline before start of trastuzumab treatment, echocardiography (ECHO)/multigated Acquisition Scan (MUGA) and measurement of plasma NT-proBNP will be performed. NT-proBNP will be measured again at 6 months and at 12 months of trastuzumab treatment. If elevations in NT-proBNP at 6 months and 12 months occur patients will be referred for ECHO/MUGA. The aim is to assess the sensitivity and specificity to detect TIC with NT-proBNP and whether ECHO/MUGA can be safely replaced by assessment of plasma NT-proBNP levels.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cardiotoxicity

Currently open trials in the same condition.

Other Vastra Gotaland Region trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06340516.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing